Figure 3.

Radiographic evaluation with axial views of pelvic CT, and changes in pain scores and the serum level of TRACP-5b during and after denosumab treatment. (A) An expansive osteolytic lesion was observed at the start of denosumab administration. The presence of bone cement that had been used at the biopsy before administration of denosumab was noted (arrow). (B) The radiodensity within the lesion was slightly increased 3 months after denosumab administration. (C) The appearance of the lesion was more radiodense 6 months after denosumab administration. (D) Osteosclerotic changes in the lesion were observed 12 months after denosumab administration. (E) The radiolucent areas were increased within the lesion nine months after denosumab discontinuation (27 months after denosumab administration). (F) The serum level of TRACP-5b was correlated with pain scores as expressed with a numeric rating score (NRS).